Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Dresen

Clinical Cardiac Electrophysiology Billings, MT Medical Doctor

NPI 1205152469 CMS profile 2782076

801 N 29Th St, Billings, MT 59101

Open in the dashboard

General payments

$8,422

207 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Dresen of Billings, MT is reported in the CMS Open Payments database as having received $8,422 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $738 33
2024 General $1,000 41
2023 General $1,523 52
2022 General $2,950 43
2021 General $351 6
2020 General $598 8
2019 General $1,261 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Dresen
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to William Dresen were reported at $738. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year William Dresen Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,261 $2,361 $585–$8,260 $163
2020 $598 $993 $247–$4,351 $114
2021 $351 $1,185 $326–$4,739 $132
2022 $2,950 $2,073 $554–$6,789 $149
2023 $1,523 $2,568 $759–$8,159 $160
2024 $1,000 $2,557 $703–$7,403 $164
2025 $738 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,715 122 payments
  2. Abbott Laboratories $3,057 36 payments
  3. Biosense Webster, Inc. $1,335 45 payments
  4. Medtronic, Inc. $150 1 payment
  5. Impulse Dynamics (USA) Inc. $143 2 payments
  6. Merit Medical Systems Inc $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,989 196 payments
  2. Travel and Lodging $2,199 10 payments
  3. Education $234 1 payment
Products named General payments · program years 2019–2025
  1. AVEIR $1,931 13 payments
  2. WATCHMAN Access System $982 42 payments
  3. WATCHMAN Structural Heart $863 6 payments
  4. WATCHMAN FLX $641 34 payments
  5. Carto 3 $600 19 payments
  6. Carto 3 System $468 19 payments
  7. ENSITE PRECISION $302 6 payments
  8. OCTARAY MAPPING CATHETER $267 5 payments
  9. WATCHMAN WATCHMAN Pro_IC $239 7 payments
  10. General - Therapies $234 1 payment
  11. Other $2,011 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,223

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$420,671

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

32.4%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 317 $333,989
Xarelto Rivaroxaban Brand 67 $75,800
Metoprolol Succinate Generic 222 $3,282
Dofetilide Generic 15 $2,604
Amiodarone Hcl Generic 47 $739
Atorvastatin Calcium Generic 82 $705
Losartan Potassium Generic 55 $648
Carvedilol Generic 88 $606
Mupirocin Generic 68 $488
Rosuvastatin Calcium Generic 22 $317

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$306,432

Medicare's payments for the services billed

Medicare patients

2,655

Average age 77

Services billed

5,962

1,177 women, 1,478 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 56%
Heart failure 45%
Ischemic heart disease 45%
Arthritis 44%
Diabetes 31%
Chronic kidney disease 29%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record